Clinical trials: Tumor Markers, Biological
Small Cell Lung Cancer Limited Stage
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer.
- Trial name
- NCT06483282
- Testing
- Adebrelimab, Apatinib Mesylate, Etoposide
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jin Ying
Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others.
- Trial name
- iFIT (NCT07649525)
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,226 people
- Sponsor
- University of Leeds
Prostatic Neoplasms
Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
The purpose of this study is to investigate cleavage products of the urokinase plasminogenactivator receptor (uPAR) in plasma from patients with castration resistant prostate cancer as a predictive marker of response to…
- Trial name
- uPARCRPC (NCT02125617)
- Testing
- Abiraterone, Prednisolone
- Where
- Denmark
- Volunteers
- 3 people
- Sponsor
- Kristoffer Rohrberg
Inoperable Early Stage Non-small Cell Lung Cancer
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC).
- Trial name
- PEARL-2 (NCT01138748)
- Testing
- hypofractionated radiation therapy
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Midgut Neuroendocrine Tumors
Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor
Midgut neuroendocrine tumours present an increasing incidence and poor survival at 5 years with limited therapeutic options for metastatic, non-operable cases.
- Trial name
- GENEBIOLuNET (NCT03667092)
- Testing
- non-drug intervention type
- Where
- France
- Volunteers
- 47 people
- Sponsor
- University Hospital, Toulouse
Cancer, Solid Tumors
Phase I Study of TAS-106 in Combo With Carboplatin
The goal of this clinical research study is to find the highest safe dose of the combination of TAS-106 and carboplatin that can be given to patients with advanced cancer or cancer that has spread.
- Trial name
- NCT00752011
- Testing
- TAS-106, Carboplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Tumor
Analysis the Positive Rate of Tumor Markers Among Physical Examination Population
To analyze the positive rate of tumor markers (TM) among health examination population in a tertiary grade A class hospital, compare the differences between different age and sex groups, and explore the possible influencing…
- Trial name
- NCT05165147
- Testing
- no intervention
- Where
- China
- Volunteers
- 26,891 people
- Sponsor
- Peking University Third Hospital
Lung Cancer
FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 (^18FDG) positron emission tomography (PET)/CT scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- ACRIN6678 (NCT00424138)
- Testing
- FDG
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- American College of Radiology Imaging Network
Kidney Cancer
Biomarkers in Urine Samples From Patients With Wilms Tumor
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.
- Trial name
- NCT01550393
- Testing
- proteomic profiling, enzyme-linked immunosorbent assay, laboratory biomarker analysis
- Volunteers
- 100 people
- Sponsor
- Children's Oncology Group
Breast Cancer
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
The goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they…
- Trial name
- AIM-BRIGHT (NCT07227233)
- Testing
- A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of California, San Diego
Lung Cancer, Cancer
'Lung Health Check' Biomarker Study
CT screening of lung cancer offers an opportunity to diagnose early stage lung cancers which is associated with better prognosis - indeterminate results delay diagnosis whilst interval imaging is awaited to assess risk of cancer.
- Trial name
- NCT04957433
- Testing
- Blood Specimen
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Trial name
- NCT02785952
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 1,207 sites in United States, Canada
- Volunteers
- 275 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899548
- Testing
- DNA methylation analysis, microarray analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
E-cigarette, Alcohol
Flavored Ready-to-Drink Alcohol Restriction in Young Adults: Behavioral and Biomarker Outcomes
This pilot randomized behavioral study evaluates the feasibility, adherence, and acceptability of an intervention to restrict flavored ready-to-drink (RTD) alcoholic beverages among young adults who regularly use both alcohol and…
- Trial name
- NCT07840625
- Testing
- Flavored Ready-to-Drink alcoholic beverage use restriction
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Glioblastoma
Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas
The aim is to classify high grade glioma by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). In order to provide more specific informations for the diagnosis and the prognosis of high grade…
- Trial name
- GLIOMIC (NCT02473484)
- Where
- France
- Volunteers
- 78 people
- Sponsor
- University Hospital, Lille
Volatile Organic Compounds, Microbiome
Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific.
- Conditions
- Volatile Organic Compounds, Microbiome, Microbioata, Breath Analysis
- Trial name
- NCT05412758
- Testing
- Oral Stimulant Drink
- Where
- United Kingdom
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer…
- Conditions
- Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
- Trial name
- NCT02274038
- Testing
- Baseline 18F-thymidine (FLT) PET/CT, Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare", Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
NSCLC, Melanoma
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib.
- Trial name
- NCT02279004
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
This phase Ib/II trial studies the side effects and best dose of trametinib when given together with pembrolizumab and to see how well they work in treating patients with non-small cell lung cancer that has come back and spread…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03225664
- Testing
- Pembrolizumab, Pharmacokinetic Study, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and genistein, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00244933
- Testing
- genistein, gemcitabine, Tumor biopsy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.